Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci

June 3, 2021 updated by: Amira Harby, Assiut University

Familial Hypercoleresremia as Risk Factor in Stemi Patient Underwent Ppci

Famulial hypercolerstremia as risk factor

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Familial hypercolerestremia ad risk factor in stemi patient who underwent Ppci

Study Type

Observational

Enrollment (Actual)

2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Assiut, Egypt
        • Amira harby

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Stemi patient

Description

Inclusion Criteria:

-all patient that underwent Ppci

Exclusion Criteria:

  • Previous ischemic patient
  • Patient with raised renal chemistry
  • Patient for CABG

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Stemi patient
Stemi patient who underwent Ppci
Genetic: Genetic
Lipid profile

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
Time Frame: One year
Correlation between familial hypercolerstremia and prognosis of patients in PPCI
One year
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
Time Frame: One year
Correlation between non familial hypercolerstremia and prognosis of patients in PPCI
One year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2020

Primary Completion (Anticipated)

August 1, 2021

Study Completion (Anticipated)

November 1, 2021

Study Registration Dates

First Submitted

March 25, 2019

First Submitted That Met QC Criteria

March 30, 2019

First Posted (Actual)

April 2, 2019

Study Record Updates

Last Update Posted (Actual)

June 7, 2021

Last Update Submitted That Met QC Criteria

June 3, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Familial hypercolerstremia

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Familial Hypercholesterolemia

Clinical Trials on Genetic

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe